Glycine substitutes and precursors for treating a psychosis

• US 20020161048A1
• Filed: 01/31/2002
• Published: 10/31/2002
• Est. Priority Date: 12/07/1995
• Status: Abandoned Application

• Current Assignee: GlyTech, Inc.
• Original Assignee: GlyTech, Inc.
• Inventors: Javitt, Daniel C.
• Application Number:
  US10/059,362
• Publication Number:
  US 20020161048A1
• Time in Patent Office: Days
• US Class Current: 514/561
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Process for treating psychosis such as schizophrenia using glycine-site fall agonists or a precursor thereof.

Claims

1. A process for treating a human patient having a psychosis which comprises administering to said human a substitute for glycine at the glycine-site or a precursor of said substitute or a glycine precursor, in an amount sufficient to potentiate NMDA receptor-mediated neurotransmission.

2. The process of claim 1 wherein the treatment increases the patient'"'"'s glycine CNS level.

3. The process of claim 1 wherein, D-serine or D-alanine is administered.

4. The process of claim 1 wherein an amino acid, polypeptide or prodrug which functions as a precursor of glycine synthesis in the CNS is administered.

5. The process of claim 1 wherein an amino acid, polypeptide or prodrug which functions as a precursor of D-serine synthesis in the CNS is administered.

6. The process of claim 1 wherein the psychosis is schizophrenia.

7. The process of claim 1 wherein a substitute for glycine is administered.

8. The process of claim 1 wherein a precursor of a substitute for glycine is administered.